- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Caribou Biosciences
Caribou Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company uses clustered regularly interspaced short palindromic repeats (CRISPR) genome editing to discover and develop immune cell-based therapeutics for cancer. It is focused on developing a pipeline of genome-edited off-the-shelf CAR-T cell and natural killer (NK) cell therapies for a range of tumor types. It also offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics and industrial biotechnology. The Company's pipeline includes CB-010, CB-011, CB-012 and CB-020.
Stock Analysis
last close
$8.55
1-mo return
51.1%
3-mo return
9.9%
avg daily vol.
479.59T
52-week high
32.65
52-week low
4.89
market cap.
$519M
forward pe
-
annual div.
-
roe
-43.4%
ltg forecast
-
dividend yield
-
annual rev.
$11M
inst own.
59.8%
